Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Resectable NSCLC × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 928 Neoplasms 652 Prostatic Neoplasms 507 Lung Neoplasms 398 Carcinoma, Non-Small-Cell Lung 361 Colorectal Neoplasms 330 Leukemia, Myeloid, Acute 265 Brain Neoplasms 232 Neoplasm Metastasis 213 Multiple Myeloma 207 Pancreatic Neoplasms 205 Carcinoma, Hepatocellular 184 Head and Neck Neoplasms 181 Melanoma 177 Ovarian Neoplasms 174 Squamous Cell Carcinoma of Head and Neck 172 Precursor Cell Lymphoblastic Leukemia-Lymphoma 162 Glioblastoma 156 Sarcoma 143 Recurrence 138 Rectal Neoplasms 138 Colonic Neoplasms 133 Triple Negative Breast Neoplasms 130 Uterine Cervical Neoplasms 129 Hematologic Neoplasms 128 Glioma 126 Urinary Bladder Neoplasms 119 Stomach Neoplasms 116 Lymphoma 114 Carcinoma, Renal Cell 110

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡